30 May 2017 - In its annual report released Tuesday, Swiss drug regulator Swissmedic says it outpaced the EMA and US FDA in approving new drugs in 2016, in part due to the agency's new fast-track procedure.

In 2016, Swissmedic approved 42 new active substances, a 50% increase over the previous year and just over 50% more than EMA recommended.

Read Regulatory Affairs Professional Society article